#Biogen Inc (BIIB) - Prohost Biotech

Biogen: FDA Approves New High Dose Regimen of SPINRAZA® (nusinersen) for Spinal Muscular Atrophy

Biogen in the NEWS Today, March 30, 2026, Biogen Inc ( BIIB ) announced that the High Dose Regimen of SPINRAZA® (nusinersen), which is comprised of 50 mg/5 mL and 28 mg/5 mL doses, was approved by th...

P

Prohost Biotech

Mar 30, 2026

Our Prohost Small Test and Anavex Life Sciences Earning Report

Anavex Life Sciences Below Today is the earnings report day for Anavex Life Sciences ( AVXL ) and Biogen ( BIIB ) . We are posting the news from Anavex Life Sciences and will continue to study the BII...

P

Prohost Biotech

Feb 12, 2025

Biogen and UCB Results: Phase 3 PHOENYCS GO Study Evaluating Dapirolizumab Pegol Demonstrated a Reduction in Systemic Lupus Erythematosus Disease Activity

Biogen & UCB Announcement Today, November 19, 2024, UCB (Euronext Brussels: ( UCB ) and Biogen ( BIIB ) presented detailed results from the Phase 3 PHOENYCS GO study evaluating dapirolizumab pegol ( D...

P

Prohost Biotech

Nov 19, 2024

UCB And Biogen Announced Positive Topline Results Phase 3 Study of Dapirolizumab Pegol for Systemic Lupus Erythematosus

UCB and Biogen Positive Results UCB (Euronext Brussels: UCB ) and Biogen Inc. ( BIIB ) announced positive topline results from the Phase 3 PHOENYCS GO study evaluating dapirolizumab pegol, a novel Fc...

P

Prohost Biotech

Sep 24, 2024

Reata Stock Holders Approved the Firm's Merger with Biogen

Reat Pharmaceuticals Merger with Biogen Reata Pharmaceuticals announced that at a special meeting held today, preliminary results indicate that the stockholders of the firm have voted to approve the C...

P

Prohost Biotech

Sep 21, 2023

Treatments for Untreatable Diseases

Prohost Letter #456 Treatments for Untreatable Diseases The revolution in biotechnology is not meant to offer just improvements on approved and marketed drugs. We are witnessing novel investigational...

P

Prohost Biotech

Jul 16, 2023

The First Post in the Series About "Treating Neurodegenerative Diseases"

Treating Neurodegenerative Disease Our priority at Prohost now is posting a series of articles about Biotech firms whose pipelines are comprised of novel products aimed at treating devastating and lif...

P

Prohost Biotech

Mar 17, 2023

From Biogen and Eisai: Lecanemab Confirmatory Phase 3 Clarity Met Primary Endpoint for Early Alzheimer’s Disease

Biogen & Eisai Co and Early Alzheimer's Disease From Tokyo and Cambridge, Eisai Co., Ltd. and Biogen Inc. ( BIIB ) announced positive topline results from Eisai’s large global Phase 3 confirmatory Cl...

P

Prohost Biotech

Sep 28, 2022

1m

18

News & Comments

Eisai and Biogen: Lecanemab for the Treament of Early Alzheimer's DIisease

Eisai and Biogen Inc: Lecanemab Eisai and Biogen Inc. (BIIB) announced that Eisai has completed the rolling submission to the U.S. FDA of a Biologics License Application (BLA) under the accelerated ap...

P

Prohost Biotech

May 10, 2022

The FDA Approval of Biogen's Alzheimer's Disease Drug and How Cassava Sciences Alzheimer's Disease Drug Differs

Biogen Product Adulelm Approved for Alzheimer's Disease The latest news regarding Alzheimer’s disease is that of the FDA’s approval of Biogen Inc's ( BIIB ) Alzheimer disease product Adulelm (aducanum...

P

Prohost Biotech

Jun 12, 2021

Annovis Bio Inc: Very Encouraging Trial Results in Neurodegenerative Diseases

Annovis Bio Inc and Neurodegenerative Diseases Annovis Bio Inc ( ANVS ) , a clinical-stage drug platform company. This firm's focus is the treatment of neurodegenerative diseases. Annovis Bio Inc anno...

P

Prohost Biotech

May 21, 2021

PTC Therapeutics' Product Risdiplam Met Trial Endpoints for the Treatment of Spinal Muscular Atrophy

PTC Therapeutics Risdiplam Results for SMA PTC Therapeutics ( PTCT ) has positive results from part 2 of the SUNFISH trial evaluating the safety and efficacy of the product risdiplam . The results dem...

P

Prohost Biotech

Nov 14, 2019

Biogen discontinued its Alzheimer's disease drug Aducanumab. The usual selloff followed

Biogen’s (BIIB) decision to discontinue the global Phase 3 trials, ENGAGE and EMERGE which is designed to evaluate the efficacy and safety of its product aducanumab in patients with Alzheimer’s diseas...

P

Prohost Biotech

Mar 21, 2019

ImmunoGen's Report and Standing. Why Biogen Is Experiencing a Selloff

ImmunoGen & Biogen News About ImmunoGen ImmunoGen (IMGN) is a creator and developer of antibody-drug conjugates (ADCs) aimed at improving cancer treatments. ImmunoGen aims to disrupt the progression...

P

Prohost Biotech

Feb 8, 2019

Biogen’s Exciting Q2 Results Highlighted Ionis (IONS) Too

The good news from Biogen’s (BIIB) Q2 exciting financial results comprised impressive news for Ionis (IONS) from the commercialization of Ionis’ approved product, Spinraza for Spinal muscular atrophy...

P

Prohost Biotech

Jul 24, 2018

Prohost Letter #410

Prohost Letter #410 JUNE PDUFA DAYS This month, the FDA will decide on the approvals of drugs belonging to companies that Prohost has picked for investment. Usually, granting approvals rallies the sto...

P

Prohost Biotech

Jun 13, 2017

Ionis Drug Spinraza Conquers Spinal Muscular Atrophy with Statistically Significant Results

Biogen (BIIB) and Ionis (IONS) announced that Spinraza (nusinersen), an antisense drug designed and developed by Ionis met its primary endpoint in Phase 3 trial of the CHERISH Study in later-onset spi...

P

Prohost Biotech

Nov 8, 2016

1m

21

News & Comments

Biogen: A Fruitful Collaboration in Gene Therapy. A Small Gene Therapy Firm That You Should Know

COLLABORATIONS Preparing for the Future, Biogen Signs a Lucrative Collaborative Agreements While Highlighting the Small Firm REGENXBIO Pursuing gene therapy, Biogen (BIIB) announced collaborations wit...

P

Prohost Biotech

May 17, 2016

Gilead: The Importance of Sovaldi Approval in Japan, A New MS Drug and More News.

WHY JAPAN APPROVAL OF GILEAD’S) HEPATITIS C DRUG SOVALDI IS IMPORTANT? As expected, Gilead’s HCV drug Sovaldi was granted approval in Japan for genotype (GT) 2 hepatitis C. Harvoni’s approval is expec...

P

Prohost Biotech

Mar 27, 2015

Immunogen Agreement with Takeda. See Also: Prothena and Biogen

IMMUNOGEN ImmunoGen’s (IMGN) Antibody drug conjugate (ADC) technology is valuable and still on demand by large drug developers who would use it to develop safer and more effective cancer therapeutics....

P

Prohost Biotech

Mar 23, 2015

1m

18